What are the therapeutic effects of Riboxil/Calilon?

Ribociclib/Calilon (Ribociclib) is a selective CDK4/6 inhibitor and is one of the targeted drugs widely recognized in the field of breast cancer in recent years. As a targeted therapy mainly used for HR-positive, HER2-negative advanced or metastatic breast cancer, its core mechanism of action is to block the overactive cell cycle pathways of cancer cells and allow abnormally replicating cells to stay in the G1 phase, thereby slowing or inhibiting tumor progression. This effect is not by directly killing cancer cells, but by precisely regulating the cell cycle to achieve long-term "cancer control" goals. Therefore, it is regarded as an important part of maintenance treatment in global guidelines.

Reboxiclib is often used in combination with endocrine drugs such as aromatase inhibitors or fulvestrant to form the advantage of "double blocking". While endocrine therapy targets hormone receptor signaling, Reboxil uses drugs to interfere with key nodes of the cell cycle, making it more difficult for tumors to proliferate through detours. Many of the latest overseas data show that this type of combined regimen can prolong disease stabilization time and improve the quality of life of some patients. With the continuous deepening of research on drug metabolism and gene pathways, it has become one of the more commonly recommended first-line or second-line options for HR+/HER2– people.

Another highly valued role is its relatively stable anti-tumor activity in different metastasis sites (such as bone metastasis, liver metastasis). Although each patient's specific presentation is different, this consistency across sites makes it commonly used in cases where long-term control of the disease rhythm is required. More importantly, Riboxiclib has certain advantages in terms of tolerability. Usually, dose adjustment within a controllable range can allow patients to adhere to treatment for a long time, which is particularly critical for chronic management-type tumors such as breast cancer.

Reference materials:https://us.kisqali.com/